Soleno Therapeutics (NASDAQ:SLNO) has been assigned a $4.00 target price by investment analysts at Maxim Group in a report released on Tuesday. The firm presently has a “buy” rating on the stock. Maxim Group’s target price points to a potential upside of 143.90% from the company’s previous close.

A number of other analysts have also recently commented on the stock. dropped their price target on shares of Soleno Therapeutics from $25.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, November 15th. ValuEngine upgraded shares of Soleno Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

Shares of Soleno Therapeutics (NASDAQ:SLNO) traded down $0.04 during mid-day trading on Tuesday, hitting $1.64. 47,900 shares of the company were exchanged, compared to its average volume of 99,045. The stock has a market cap of $17.80, a PE ratio of -1.03 and a beta of 5.52. Soleno Therapeutics has a 12 month low of $1.32 and a 12 month high of $4.20.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($0.24) EPS for the quarter. Soleno Therapeutics had a negative net margin of 1,389.76% and a negative return on equity of 54.11%.

In other news, Director Edgar Engleman bought 1,085,480 shares of the stock in a transaction on Friday, December 15th. The shares were acquired at an average cost of $1.84 per share, for a total transaction of $1,997,283.20. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 69.75% of the company’s stock.

An institutional investor recently bought a new position in Soleno Therapeutics stock. Birchview Capital LP bought a new position in Soleno Therapeutics Inc (NASDAQ:SLNO) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 678,428 shares of the company’s stock, valued at approximately $1,032,000. Soleno Therapeutics makes up approximately 0.6% of Birchview Capital LP’s investment portfolio, making the stock its 14th biggest holding. Birchview Capital LP owned about 6.78% of Soleno Therapeutics as of its most recent filing with the SEC.

COPYRIGHT VIOLATION WARNING: This article was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://theolympiareport.com/2018/02/13/maxim-group-reiterates-4-00-price-target-for-soleno-therapeutics-slno.html.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, formerly Capnia, Inc, is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief.

Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.